Search results for: '2026 deal alliance review'

Academic and Non-Profit Partnering Terms and Agreements 2021-2026 provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

Essential Benchmark Data for Dealmakers  | Global coverage | Updated to 2026 | 11+ years of royalty rates | Deal financials | Contract documents | Royalty rate trends

Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2020 to 2025

Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals. 

Track JV activity across pharma and biotech with real-world examples, financial terms, and partnering trends—includes access to contract documents where available.

Bioinformatics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report offers in-depth insights and exclusive access to clinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Gastrointestinal Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2016 to 2025

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.